J 2023

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

DUCREUX, M., G. K. ABOU-ALFA, T. BEKAII-SAAB, J. BERLIN, A. CERVANTES et. al.

Basic information

Original name

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Authors

DUCREUX, M., G. K. ABOU-ALFA, T. BEKAII-SAAB, J. BERLIN, A. CERVANTES, T. DE BAERE, C. ENG, P. GALLE, S. GILL, T. GRUENBERGER, K. HAUSTERMANS, A. LAMARCA, P. LAURENT-PUIG, J. M. LLOVET, F. LORDICK, T. MACARULLA, D. MUKHERJI, K. MURO, Radka LORDICK OBERMANNOVÁ (203 Czech Republic, belonging to the institution), J-M. CONNOR, E. M. REILLY, P. OSTERLUND, P. PHILIP, G. PRAGER, E. RUIZ-GARCIA, B. SANGRO, T. SEUFFERLEIN, J. TABERNERO, C. VERSLYPE, H. WASAN and E. VAN CUTSEM

Edition

ESMO OPEN, AMSTERDAM, ELSEVIER, 2023, 2059-7029

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.300 in 2022

RIV identification code

RIV/00216224:14110/23:00133415

Organization unit

Faculty of Medicine

UT WoS

001045033500001

Keywords in English

hepatocellular carcinoma; liver transplantation; chemoembolisation; immunotherapy; radioembolisation

Tags

Tags

International impact, Reviewed
Změněno: 2/2/2024 10:59, Mgr. Tereza Miškechová

Abstract

V originále

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.